Overview

The purpose of this study is to:

• evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
• characterize the single-dose pharmacokinetics (PK) of ALN-4285

Eligibility

Inclusion Criteria:

• Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
• Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator

Exclusion Criteria:

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
• Has total bilirubin \>ULN
• Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
• Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening
• Has received an investigational agent within the last 30 days or 5 half-lives